Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
The Company anticipates dosing the first patient in the trial in the fourth quarter of this year.
- The Company anticipates dosing the first patient in the trial in the fourth quarter of this year.
- We eagerly await reaching each higher dose level in this trial, said Andrew Mazar, PhD, Monopars Chief Scientific Officer.
- Camsirubicin is a novel analog of doxorubicin, and doxorubicin is known to work through a dose-dependent mechanism, where higher quantities yield more anti-cancer effect.
- If successful in ASTS, there are 13 other potential cancer indications for camsirubicin where doxorubicin is already FDA-approved, said Chandler Robinson, MD, Monopars Chief Executive Officer.